PRNewsWire · LLY · October 19, 2026

Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis

Get the app for more

Explore stock news, insights and company research.